| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.004 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.085 | 0.005 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.005 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.007 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.009 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.7 | 0.01 |